Impact of inhibiting ileal apical versus basolateral bile acid transport on cholesterol metabolism and atherosclerosis in mice

Digestive Diseases

Volumn 33, Issue 3, 2015, Pages 382-387

  Dawson, Paul A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Enterohepatic circulation; Intestine; Liver

Indexed keywords

BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; TAUROCHOLIC ACID; APOLIPOPROTEIN E; CARRIER PROTEIN; COTRANSPORTER; CYP7A1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE; LOW DENSITY LIPOPROTEIN RECEPTOR; ORGANIC ANION TRANSPORTER; ORGANIC SOLUTE TRANSPORTER ALPHA, MOUSE; ORGANIC SOLUTE TRANSPORTER BETA, MOUSE; SODIUM-BILE ACID COTRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APICAL MEMBRANE; BASOLATERAL MEMBRANE; BILE ACID METABOLISM; BILIARY EXCRETION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL ATHEROSCLEROSIS; FEMALE; HYPERCHOLESTEROLEMIA; ILEUM; LIPID HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ATHEROSCLEROSIS; CHEMISTRY; FECES; GENE EXPRESSION; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; FECES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; ILEUM; LIVER; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RECEPTORS, LDL; SIGNAL TRANSDUCTION; SYMPORTERS; TAUROCHOLIC ACID;

EID: 84930582672     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000371691     Document Type: Conference Paper

References (40)

1. Dawson PA, Lan T, Rao A: Bile acid transporters. J Lipid Res 2009; 50: 2340-2357.
2. Westergaard H, Dietschy JM: The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest 1976; 58: 97-108.
3. Wong MH, Oelkers P, Craddock AL, Dawson PA: Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem 1994; 269: 1340-1347.
4. Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, Ballatori N: The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005; 280: 6960-6968.
5. Wang W, Seward DJ, Li L, Boyer JL, Ballatori N: Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc Natl Acad Sci USA 2001; 98: 9431-9436.
6. Chiang JY: Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966.
7. Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-1659.
8. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
9. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
10. Buchwald H, Rudser KD, Williams SE, Michalek VN, Vagasky J, Connett JE: Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010; 251: 1034-1040.
11. Oelkers P, Kirby LC, Heubi JE, Dawson PA: Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99: 1880-1887.
12. Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS: Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003; 278: 33920-33927.
13. Jung D, Inagaki T, Dawson PA, Kliewer SA, Mangelsdorf DJ, Moschetta A: FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res 2007; 48: 2693-2700.
14. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
15. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-515.
16. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-526.
17. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225.
18. Lundasen T, Galman C, Angelin B, Rudling M: Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-536.
19. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ: Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48: 2664-2672.
20. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL: Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012; 56: 1034-1043.
21. Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA: The organic solute transporter -, Ost-Ost? is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci USA 2008; 105: 3891-3896.
22. Ballatori N, Fang F, Christian WV, Li N, Hammond CL: Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 2008; 295:G179-G186.
23. Lan T, Rao A, Haywood J, Kock ND, Dawson PA: Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. J Hepatol 2012; 57: 359-365.
24. Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Muller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD: The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol 2007; 21: 1603-1616.
25. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582. e571.
26. Meir KS, Leitersdorf E: Atherosclerosis in the apolipoprotein-E-deficient mouse: A decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-1014.
27. Veniant MM, Withycombe S, Young SG: Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arterioscler Thromb Vasc Biol 2001; 21: 1567-1570.
28. Shepherd J, Packard CJ, Bicker S, Lawrie TD, Morgan HG: Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980; 302: 1219-1222.
29. Lan T, Haywood J, Dawson PA: Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE-/-mice. Atherosclerosis 2013; 229: 374-380.
30. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG: Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000; 106: 1501-1510.
31. Miyake JH, Duong-Polk XT, Taylor JM, Du EZ, Castellani LW, Lusis AJ, Davis RA: Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol 2002; 22: 121-126.
32. Lee MR, Lim CJ, Lee YH, Park JG, Sonn SK, Lee MN, Jung IH, Jeong SJ, Jeon S, Lee M, Oh KS, Yang Y, Kim JB, Choi HS, Jeong W, Jeong TS, Yoon WK, Kim HC, Choi JH, Oh GT: The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice. Nat Commun 2014; 5: 4410.
33. Meissner M, Wolters H, de Boer RA, Havinga R, Boverhof R, Bloks VW, Kuipers F, Groen AK: Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. Atherosclerosis 2013; 228: 117-123.
34. Terasaka N, Miyazaki A, Kasanuki N, Ito K, Ubukata N, Koieyama T, Kitayama K, Tanimoto T, Maeda N, Inaba T: ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterollowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 2007; 190: 239-247.
35. Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M: Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J 2003; 17: 265-267.
36. Bhat BG, Rapp SR, Beaudry JA, Napawan N, Butteiger DN, Hall KA, Null CL, Luo Y, Keller BT: Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/-mice by SC-435. J Lipid Res 2003; 44: 1614-1621.
37. Braun A, Yesilaltay A, Acton S, Broschat KO, Krul ES, Napawan N, Stagliano N, Krieger M: Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 2008; 198: 77-84.
38. Tietge UJ, Groen AK: Role the TICE? Advancing the concept of transintestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 2013; 33: 1452-1453.
39. Temel RE, Brown JM: Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol 2012; 23: 85-90.
40. Dietschy JM, Turley SD: Control of cholesterol turnover in the mouse. J Biol Chem 2002; 277: 3801-3804.